ArchPoint Investors’s Ginkgo Bioworks DNA Stock Holding History

ArchPoint Investors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-780	Closed	-$52.7K	–	70
2023 Q4	$52.7K	Hold	780	–	–	0.02%	52
2023 Q3	$56.5K	Hold	780	–	–	0.02%	54
2023 Q2	$58K	Hold	780	–	–	0.02%	54
2023 Q1	$41.5K	Hold	780	–	–	0.02%	54
2022 Q4	$52.7K	Buy	+780	New	+$71.7K	0.03%	54

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ArchPoint Investors's DNA Position: Q1 2024 in Review

ArchPoint Investors sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 780 shares — an estimated $52.7K sold.

ArchPoint Investors first reported a position in DNA in Q4 2022 and held it in 5 quarters. The position peaked at $58K in Q2 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

ArchPoint Investors reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
ArchPoint Investors sold 780 Ginkgo Bioworks shares in Q1 2024, an estimated $52.7K.
ArchPoint Investors first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 5 quarters.
ArchPoint Investors's Ginkgo Bioworks position peaked at $58K in Q2 2023.
342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on ArchPoint Investors's 13F filing for Q1 2024, filed 14 May 2024.